Cornea & Anterior Segment Services, L. V. Prasad Eye Institute, Mithu Tulsi Chanrai Campus, Bhubaneswar, India.
Semin Ophthalmol. 2023 Jan;38(1):9-14. doi: 10.1080/08820538.2022.2112698. Epub 2022 Aug 21.
This exhaustive review of published literature aims to put forth the current understanding, and experiences of the role Rho-kinase inhibitors play in the management of corneal endothelial disorders.
A meticulous search for PubMed and Medline databases was carried out using keywords 'rho-kinase inhibitors', 'corneal endothelial disorders', 'rho-kinase inhibitors in corneal endothelial disorders', and 'fuchs endothelial corneal dystrophy'. The articles published in last five years relevant to the area of interest were selected and compiled in a chronological order to write this review.
Published research shows the proven role of rho-kinase inhibitors in promoting endothelial proliferation and suppressing its apoptosis. It has shown to be effective in the treatment of endothelial diseases and endothelial cell loss due to other causes in small clinical studies. It has also shown to promote growth of human corneal endothelial cell culture suitable for transplantation. The side effects of topical rho-kinase inhibitors are minimal and self-limiting.
Rho-kinase inhibitors show immense promise in providing a non-surgical therapy for treatment of endothelial disorders. If consistent results are demonstrated through large clinical trials then this can be a major breakthrough in treating endothelial decompensation and reduce our dependence on endothelial keratoplasty for the same.
本文对已发表的文献进行了全面回顾，旨在阐述 Rho 激酶抑制剂在角膜内皮疾病管理中的作用及其目前的认识和经验。
使用关键词“Rho 激酶抑制剂”、“角膜内皮疾病”、“Rho 激酶抑制剂在角膜内皮疾病中的作用”和“Fuchs 内皮角膜营养不良”，对 PubMed 和 Medline 数据库进行了细致的搜索。选择了过去五年内与研究领域相关的已发表文章，并按照时间顺序进行编译，以撰写这篇综述。
已发表的研究表明，Rho 激酶抑制剂在促进内皮细胞增殖和抑制其凋亡方面具有明确的作用。在一些小型临床研究中，它已被证明对内皮疾病和其他原因引起的内皮细胞丧失有效。它还被证明可以促进适合移植的人角膜内皮细胞培养物的生长。局部 Rho 激酶抑制剂的副作用最小且具有自限性。
Rho 激酶抑制剂在为内皮疾病提供非手术治疗方面显示出巨大的潜力。如果大型临床试验能得出一致的结果，那么这将是治疗内皮失代偿方面的重大突破，并减少我们对内皮角膜移植术的依赖。
